BioCentury
ARTICLE | Financial News

Allena proposes $92M IPO

October 9, 2017 7:53 PM UTC

Kidney disease company Allena Pharmaceuticals Inc. (Newton, Mass.) proposed to raise up to $92 million in an IPO on NASDAQ underwritten by Credit Suisse, Jefferies, Wedbush and Cowen.

Allena's lead candidate, ALLN-177, is an oral recombinant oxalate degrading enzyme. In 1Q18, the company expects to begin a Phase III program to treat hyperoxaluria; it expects data from the first of two planned studies in 2H19...

BCIQ Company Profiles

Allena Pharmaceuticals Inc.